Altoida Unveils New Brand Identity with Redesigned Logo and Website | New
WASHINGTON, September 3, 2021 / PRNewswire-PRWeb / – Altoida, Inc., the world leader in precision neurology, today announced the launch of its new brand identity, redesigned logo and website. These changes come at a time when the company is making rapid scientific progress and expanding its global commercial presence.
“In 2021, our company has become a global pioneer in precision neurology,” said Travis Bond, CEO of Altoida. “This year has catalyzed a fundamental shift in the way we think about basic science, technology and our company’s unprecedented opportunity to improve the lives of those we serve. to launch our updated brand to support this ambition. “
The new logo is designed to reflect Altoida’s commitment to accurate and democratized data, and to focus on creating reliable and accessible products for businesses and consumers. The updated color palette is inviting and uplifting, while still being functional and accessible to the aging communities that Altoida and their products support. The updated color palette green nods to the original green used in the company’s legacy brand, paying homage to the company’s scientific roots for decades.
“This significant change to our brand allows us to better communicate who we are and what we market to those we serve,” said Henri peck, Director of Global Marketing at Altoida. “Our new identity demonstrates our commitment to innovate in precision neurology, adapt to the needs of our global customers, and operate with data as a guide – pillars we use not only to describe the products we create, but the values. fundamentals of our business too. “
The rebranding follows several important news for Altoida. In July 2021, the company won the designation of revolutionary device of the United States Food and Drug Administration (FDA) for the development of their industry-first diagnostic to help predict whether or not a person aged 55 and over with mild cognitive impairment will convert to dementia or not. ‘Alzheimer’s. The company also recently funding obtained and a partnership with Eisai Innovation, Inc., a strategic investment subsidiary of Eisai, Inc., to further accelerate their research in the predictive diagnosis of neurodegenerative diseases, such as Alzheimer’s disease and other dementias.
About Altoida, Inc.
Altoida, Inc is setting a new benchmark in brain health with Precision Neurology. Our innovative approach combines new digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI). The result is our validated device and platform, built on over twenty years of cutting-edge scientific research. Our products are backed by peer-reviewed publications and multinational clinical trials, and are developed by our expert team of scientists, clinicians and engineers. Altoida, Inc. is funded by M-Ventures, Eisai Innovation, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners. To learn more about Altoida, please visit http://www.altoida.com and connect with us on LinkedIn and Twitter.
Henri peck, Altoida, Inc., +1 (240) 720-7538, [email protected]
SOURCE Altoida, Inc.